The antimicrobial resistance market was valued at $4.6 billion in 2022 and is estimated to reach $9.5 billion by 2032, exhibiting a CAGR of 7.6% from 2023 to 2032. Antimicrobial resistance (AMR), also known as drug resistance is the resistance developed by the bacteria, viruses, fungi, and parasites to the available antimicrobial drugs over a period. It is a comprehensive concept and often encompasses resistance to antibacterial, antiviral, antiparasitic, and antifungal drugs. The microorganisms which become resistant to most of the antimicrobials are often referred to as superbugs. Few examples of superbugs include MRSA (methicillin-resistant staphylococcus aureus), Clostridium difficile (C. diff), and the bacteria that cause multi-drug-resistant tuberculosis.
Resistance to antimicrobials often develops in microorganisms over time because of genetic changes that occur during their reproductive cycles. Changes in the DNA may result in barriers that prevent antimicrobials from reaching the cell of microbe or may develop the ability to create enzymes that are able to counteract effects of the antimicrobial.
Antimicrobial resistance is significantly influenced by the overuse of antibiotics. Resistance to antimicrobials is heavily influenced by the excessive use of antibiotics. There is a higher chance of leaving behind resilient microbes when antibiotic treatments are too short, weak, or inappropriate for the specific infection. Moreover, antibiotics are often prescribed unnecessarily for viral infections such as colds, flu, or mild illnesses, which do not respond to antibiotics. Overprescribing leads to the unnecessary exposure of bacteria to these drugs, increasing the risk of resistance.
In addition, repeated exposure of microbes to antimicrobials, as well as contact with other already resistant microbes, provides numerous opportunities for resistance to develop and spread. Therefore, it is crucial to use antimicrobials appropriately to minimize the risk of antimicrobial resistance.
Furthermore, the rise in government initiatives to combat this antimicrobial resistance is the key factor which boosts the growth of the antimicrobial resistance market. For instance, the Global Antimicrobial Resistance Research & Development (AMR R&D) Hub is a collaboration of governments, non-governmental donor organizations, and intergovernmental organizations that use a One Health strategy to solve difficulties and increase coordination and collaboration in global AMR R&D.
On the other hand, the high cost of these novel therapeutics is expected to act as a restraint to the market growth. R&D of these antimicrobial candidates is expensive leading to higher cost of the products. This becomes difficult for people in lower-income countries to afford high-cost advanced antimicrobials and avoid antimicrobial resistance which may hinder market growth to some extent.
However, robust pipeline of antibiotic treatments to combat antimicrobial resistance is expected to offer lucrative opportunities for the growth of the market during the forecast period. Researchers and pharmaceutical companies have developed innovative therapies and treatments to combat antimicrobial resistance, providing potential new treatment options. In addition, the development of innovative antibiotics offers healthcare providers a wider range of treatment options. Having multiple effective antibiotics with different mechanisms of action can improve the chances of successfully treating infections, even those caused by highly resistant bacteria. This is expected to effectively overcome the threat of antimicrobial resistance and thus contribute to market growth during the forecast period.
The antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others.
On the basis of on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global antimicrobial resistance market are Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc.
Resistance to antimicrobials often develops in microorganisms over time because of genetic changes that occur during their reproductive cycles. Changes in the DNA may result in barriers that prevent antimicrobials from reaching the cell of microbe or may develop the ability to create enzymes that are able to counteract effects of the antimicrobial.
Antimicrobial resistance is significantly influenced by the overuse of antibiotics. Resistance to antimicrobials is heavily influenced by the excessive use of antibiotics. There is a higher chance of leaving behind resilient microbes when antibiotic treatments are too short, weak, or inappropriate for the specific infection. Moreover, antibiotics are often prescribed unnecessarily for viral infections such as colds, flu, or mild illnesses, which do not respond to antibiotics. Overprescribing leads to the unnecessary exposure of bacteria to these drugs, increasing the risk of resistance.
In addition, repeated exposure of microbes to antimicrobials, as well as contact with other already resistant microbes, provides numerous opportunities for resistance to develop and spread. Therefore, it is crucial to use antimicrobials appropriately to minimize the risk of antimicrobial resistance.
Furthermore, the rise in government initiatives to combat this antimicrobial resistance is the key factor which boosts the growth of the antimicrobial resistance market. For instance, the Global Antimicrobial Resistance Research & Development (AMR R&D) Hub is a collaboration of governments, non-governmental donor organizations, and intergovernmental organizations that use a One Health strategy to solve difficulties and increase coordination and collaboration in global AMR R&D.
On the other hand, the high cost of these novel therapeutics is expected to act as a restraint to the market growth. R&D of these antimicrobial candidates is expensive leading to higher cost of the products. This becomes difficult for people in lower-income countries to afford high-cost advanced antimicrobials and avoid antimicrobial resistance which may hinder market growth to some extent.
However, robust pipeline of antibiotic treatments to combat antimicrobial resistance is expected to offer lucrative opportunities for the growth of the market during the forecast period. Researchers and pharmaceutical companies have developed innovative therapies and treatments to combat antimicrobial resistance, providing potential new treatment options. In addition, the development of innovative antibiotics offers healthcare providers a wider range of treatment options. Having multiple effective antibiotics with different mechanisms of action can improve the chances of successfully treating infections, even those caused by highly resistant bacteria. This is expected to effectively overcome the threat of antimicrobial resistance and thus contribute to market growth during the forecast period.
The antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others.
On the basis of on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global antimicrobial resistance market are Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antimicrobial resistance market analysis from 2022 to 2032 to identify the prevailing antimicrobial resistance market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the antimicrobial resistance market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global antimicrobial resistance market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Indication
- Complicated Urinary Tract Infections (cUTI)
- Blood stream infections
- Acute bacterial skin and skin structure infections (ABSSSI)
- Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
- Community acquired pneumonia (CAP)
- Others
By Drug Class
- Combination therapies
- Tetracyclines
- Cephalosporins
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Others
By Mechanism of Action
- Protein Synthesis Inhibitors
- Cell Wall Synthesis Inhibitors
- Others
By Pathogen
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Enterococcus Spp
- Others
- Escherichia coli
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Pfizer Inc.
- Cumberland Pharmaceuticals
- Acurx Pharmaceuticals, Inc.
- Paratek Pharmaceuticals Inc
- Alkem Laboratories Ltd.
- Nabriva Therapeutics plc
- Innoviva, Inc
- Basilea Pharmaceutica Ltd
- Wockhardt Limited.
- Merck & Co., Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS
CHAPTER 5: ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN
CHAPTER 6: ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION
CHAPTER 7: ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION
CHAPTER 8: ANTIMICROBIAL RESISTANCE MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
The antimicrobial resistance market is likely to experience a significant growth rate of 7.6% from 2023-2032 owing to increasing market demand from pharmaceutical sectorAntimicrobial resistance (AMR) is referred to the resistance developed by the microorganisms against the antibiotics over time. Antibiotics are often prescribed on a large scale for treatment of various bacterial infections and sometimes may be misused in treatment of viral infections. It has proved to be a global threat to the healthcare sector and is anticipated to grow at an alarming rate. Such misuse of antibiotics is the major factor that causes antimicrobial resistance among microorganisms. Thus, there is an urgent need for innovative antibiotics that are effective against these resistant bacteria, which propels the growth of the antimicrobial resistance market.
Key factors driving the growth of the antimicrobial resistance market are overuse and misuse of antibiotics, rise in prevalence of antimicrobial resistance bacterial infections and growth in burden of antimicrobial resistance. The burden of antimicrobial resistance is rising at an alarming rate which leads to severe negative effects on the healthcare systems around the globe.
In addition, according to the National Infection & Death Estimates for Antimicrobial Resistance, in the U. S., more than 2.8 million antimicrobial-resistant infections occur each year. Such huge burden of antimicrobial resistance leads to high treatment cost, increased mortality and morbidity, limited treatment options, and increased hospital stays. Also, the available treatment becomes ineffective which demands new and novel antibiotics that can overcome the AMR burden and propels the market growth.
Furthermore, the antimicrobial resistance market is expected to experience significant growth opportunities in developing regions over the next few years. The developing regions are working towards improving their healthcare infrastructure for which they need to set up and expand medical facilities, such as hospitals, clinics and outpatient care centers. This growth in medical facilities creates a need for novel antimicrobials, which are needed for effective patient care. This boosts market growth.
In addition, there is a surge in research and development activities to develop novel antibiotics medications which can be used in the treatment of resistant bacteria are anticipated to contribute to the market growth during the forecast period.
The antimicrobial resistance market is segmented on the antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. Based on on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others.
On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc. The players in the market have been actively engaged in the adoption of various strategies such as collaboration, funding, acquisition, product approval, product upgrade/development, agreement and product launch to remain competitive and gain an advantage over the competitors in the market.
For instance, in July 2020, Nabriva Therapeutics plc announced that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of Xenleta (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.
Key Market Insights
By drug class, the combination therapies segment was the highest revenue contributor to the market whereas the others segment is anticipated to be the fastest growing segment during the forecast period.By pathogen, the Escherichia coli segment dominated the global market whereas the Klebsiella pneumoniae segment is expected to be the fastest-growing segment during the forecast period.
By indication, the complicated urinary tract infections (cUTI) segment dominated the market in 2022, whereas the hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP & VABP) segment is anticipated to grow at a fastest rate during the forecast period.
By mechanism of action, the cell wall synthesis inhibitors segment dominated the market in 2022 and is anticipated to be the fastest growing segment during the forecast period.
Based on region, North America garnered the largest revenue share in 2022, and Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Pfizer Inc.
- Cumberland Pharmaceuticals
- Acurx Pharmaceuticals, Inc.
- Paratek Pharmaceuticals Inc
- Alkem Laboratories Ltd.
- Nabriva Therapeutics plc
- Innoviva, Inc
- Basilea Pharmaceutica Ltd
- Wockhardt Limited.
- Merck & Co., Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
